Epidermal growth factor receptor as predicting factor on biochemical recurrence after radical prostatectomy: A prospective study

Korean Journal of Urology

Volumn 49, Issue 11, 2008, Pages 974-980

  Lee, Jeong Woo ^a   Cho, Kang Su ^b   Han, Kyung Seok ^b   Kim, Eun Kyoung ^b   Joung, Jae Young ^b   Seo, Ho Kyung ^b   Chung, Jinsoo ^b   Park, Weon Seo ^b   Lee, Kang Hyun ^b  

^a Seoul National University Hospital   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

Biochemical recurrence; Epidermal growth factor receptor; Prostate cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE MARKER; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PROSTATE CANCER; PROTEIN EXPRESSION; RADICAL RETROPUBIC PROSTATECTOMY; SEMINAL VESICLE; SURVIVAL TIME;

EID: 57049174583     PISSN: 04944747     EISSN: None     Source Type: Journal    
DOI: 10.4111/kju.2008.49.11.974     Document Type: Article

References (30)

1. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71
2. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17:1499-507
3. Hong JH, Lee HM, Choi HY. The predictors of biochemical recurrence and metastasis following radical perineal prostatectomy in clinically localized prostate cancer. Korean J Urol 2005;46:1161-7
4. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002;7 (Suppl 4):31-9
5. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438-44
6. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 2007;14:295-304
7. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94:1593-611
8. Merlino GT. Epidermal growth factor receptor regulation and function. Semin Cancer Biol 1990;1:277-84
9. Haeder M, Rotsch M, Bepler G, Henning C, Havemann K, Heimann B, et al. Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res 1988;48:1132-6
10. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37
11. Boonstra J, De Laat SW, Ponec M. Epidermal growth factor receptor expression related to differentiation capacity in normal and transformed keratinocytes. Exp Cell Res 1985;161:421-33
12. Greenberg SD, Fraire AE, Kinner BM, Johnson EH. Tumor cell type versus staging in the prognosis of carcinoma of the lung. Pathol Annu 1987;22:387-405
13. Newby JC, Johnston SR, Smith IE, Dowsett M. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997;3:1643-51
14. Chen X, Yeung TK, Wang Z. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res Commun 2000;277:757-63
15. Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P, et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 1997;17:613-9
16. Magne N, Pivot X, Bensadoun RJ, Guardiola E, Poissonnet G, Dassonville O, et al. The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy. Eur J Cancer 2001;37:2169-77
17. Mckenzie SJ. Diagnostic utility of oncogenes and their products in human cancer. Biochem Biophys Acta 1991;1072: 193-214
18. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, et al. Regulation of prostatic growth and function by peptide growth factors. Prostate 1996;28:392-405
19. Hiramatsu M, Kashimata M, Minami N, Sato A, Murayama M, Minami N. Androgenic regulation of epidermal growth factor in the mouse ventral prostate. Biochem Int 1998;17: 311-7
20. Nishi N, Oya H, Matsumoto K, Nakamura T, Miyanaka H, Wada F. Changes in gene expression of growth factors and their receptors during castration-induced involution and androgen-induced regrowth of rat prostate. Prostate 1996;28:139-52
21. Fowler JE Jr, Lau JL, Ghosh L, Mills SE, Mounzer A. Epidermal growth factor and prostatic carcinoma: an immunohistochemical study. J Urol 1988;139:857-61
22. Yang Y, Chisholm GD, Habib FK. Epidermal growth factor and transforming growth factor alpha concentrations in BPH and cancer of the prostate: their relationship with tissue androgen levels. Br J Cancer 1993;67:152-5
23. Robertson CN, Roberson KM, Herzberg AJ, Kerns BJ, Dodge RK, Paulson DF. Differential immunoreactivity of transforming growth factor alpha in benign, dysplastic and malignant prostatic tissues. Surg Oncol 1994;3:237-42
24. Fox SB, Persad RA, Coleman N, Day CA, Silcocks PB, Collins CC. Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma. Br J Urol 1994;74:214-20
25. MacDonald A, Habib FK. Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br J Cancer 1992;65:177-82
26. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, et al. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1995;1:545-50
27. Barton J, Blackledgc G, Wakeling A. Growth factors and their receptors: new targets for prostate cancer therapy. Urology 2001;58(2 Suppl 1):114-22
28. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005;23:455-60
29. Miller K, Raabe N, Trachtenberg J, Trump D, Wilding G, Das-Gupta A. ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is well tolerated in combination with mitoxantrone and prednisone in patients with hormone-refractory prostate cancer (HRPC). Ann Oncol 2002;13(Suppl 5):91, abstract 327
30. Soulie P, Trump D, Wilding G, Small E, Das-Gupta A. ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with docetaxel and estramustine in patients with hormone-refractory prostate cancer (HRPC). Ann Oncol 2002;13(Suppl 5):91, abstract 328